Drugs

, Volume 72, Issue 8, pp 1057–1073

The Role of Capecitabine in Locally Advanced Rectal Cancer Treatment

An Update
  • Carlos Fernández-Martos
  • Miquel Nogué
  • Paloma Cejas
  • Víctor Moreno-García
  • Ana Hernández Machancoses
  • Jaime Feliu
Review Article

DOI: 10.2165/11633870-000000000-00000

Cite this article as:
Fernández-Martos, C., Nogué, M., Cejas, P. et al. Drugs (2012) 72: 1057. doi:10.2165/11633870-000000000-00000

Abstract

Preoperative infusional 5-fluorouracil (5-FU) and concurrent radiation therapy (RT) followed by total mesorectal surgery is the current standard of care for locally advanced rectal cancer (LAR). When compared with postoperative 5-FU-based chemoradiation, this strategy is associated with significantly lower rates of local relapse, lower toxicity and better compliance. Capecitabine is a rationally designed oral prodrug that is converted into 5-FU by intracellular thymidine phosphorylase. Substitution of infusional 5-FU with capecitabine is an attractive option that provides a more convenient administration schedule and, possibly, increased efficacy. Indeed, incorporation of capecitabine in combined modality neoadjuvant therapy for LAR has been under intense investigation during the last 10 years. Phase I and II clinical trials showed that a regimen consisting of capecitabine 825mg/m2 twice daily for 7 days/week continuous oral administration in combination with RT is an active and well tolerated regimen, thereby being the preferred concurrent regimen. The definitive demonstration that efficacy of capecitabine/RT is similar to 5-FU/RT has been provided by the NSABP-R-04 and the German Margit trials. One approach to improve outcomes in rectal cancer is to deliver a second RT-sensitizing drug with effective systemic activity. Oxaliplatin and irinotecan are therefore good candidates. However, two phase III trials demonstrated that incorporation of oxaliplatin to capecitabine with RT did not improve early outcomes and, by contrast, increased toxicity. Capecitabine has also been combined with irinotecan. This regimen showed encouraging results in phase I and II clinical trials, which led to an ongoing phase III clinical trial.

New strategies with induction chemotherapy with or without chemo-radiation prior to surgery are currently under investigation. Whether or not capecitabine has a role in this setting is being investigated in ongoing trials. Incorporation of agents directed towards new targets, such as anti-epidermal growth factor receptor (EGFR) antibodies or antiangiogenic agents, in combination preoperative regimens, is being hampered by results of early trials in which efficacy outcomes with cetuximab were poor and an excessive rate of surgical complications with bevacizumab was observed. The lack of improvements in efficacy with the addition of cetuximab or bevacizumab in the adjuvant treatment of colon cancer led to concerns about further devel-opment of these agents in rectal cancer. The role of capecitabine in the postoperative adjuvant setting is the aim of the ongoing Dutch SCRIPT trial. The prediction of response associated with capecitabine has been based on expression of thymidylate synthase and dihydropyrimidine dehydrogenase, as well as on gene expression arrays. All these procedures require further validation and should be considered as investigational. In conclusion, capecitabine can safely and effectively replace intravenous continuous infusion of 5-FU in the preoperative chemoradiation setting for rectal cancer management. The addition of other new antineoplastic agents to a fluoropy-rimidine-based regimen remains investigational.

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Carlos Fernández-Martos
    • 1
  • Miquel Nogué
    • 2
  • Paloma Cejas
    • 3
  • Víctor Moreno-García
    • 3
    • 4
  • Ana Hernández Machancoses
    • 5
  • Jaime Feliu
    • 3
  1. 1.Servicio de Oncología MédicaFundación Instituto Valenciano de OncologíaValenciaSpain
  2. 2.Servicio de Oncología MédicaHospital de GranollersBarcelonaSpain
  3. 3.Servicio de Oncología MédicaHospital Universitario La Paz (IdiPAZ)MadridSpain
  4. 4.Drug Development UnitRoyal Marsden HospitalSurreyUK
  5. 5.Servicio de Oncología RadioterapiaERESA-Hospital General UniversitarioValenciaSpain